Presentation Title

Combination Drug Therapy for Non-Small Cell Lung Cancer (NSCLC)

Start Date

November 2016

End Date

November 2016

Location

Surge 171

Type of Presentation

Oral Talk

Abstract

Cancer is an alarming global health concern. In 2016, it is estimated that approximately 27% of the cancer deaths will be due to lung and bronchus cancer. Drug resistance is a trending problem encountered by pharmaceutical and biotechnology companies developing anticancer drugs. It has been observed that chemotherapy might have reached a therapeutic glass ceiling in metastatic NSCLC. Cancer resistance can be acquired through dysfunctional DNA repair mechanism, epigenetics, cell-death inhibition, and drug efflux. Combination therapy brings the opportunity to re-establish current and obsolete FDA approved anti-cancer drugs by reducing the likelihood of cancer cells to develop resistance, and eliminating the dose-related off-target toxicities. This project aims to identify the novel drug combinations that would be capable of tackling the problems associated with acquired drug resistance. Here, we examined the response of NSCLC cell lines A549, H4006, H460, and H358 to independent treatment with FDA approved drugs: pemetrexed, quinacrine, cisplatin, paclitaxel, sorafenib, erlotinb, Px-866, oxaliplatin, and minocycline, in varying concentrations. The viabilities of the cell lines were assessed using cytotoxity assay and the IC50 values were obtained using the software Graphpad prism 4. Combination therapy was applied to the cell lines that expressed resistance to the drug, displayed an IC50 value above 10 µM, and the viability of the cell lines was assessed with the cytotoxicity assay. Results indicated that cell lines H460, H4006, H358 had an IC50 value of 4 µM when subjected to quinacrine. Though, H358 and H4006 cell lines yielded resistance to cisplatin. Quinacrine-cisplatin combination therapy was applied to the H358 cell line, but the viability was similar to that of independent treatment with quinacrine and cisplatin.

This document is currently not available here.

Share

COinS
 
Nov 12th, 11:45 AM Nov 12th, 12:00 PM

Combination Drug Therapy for Non-Small Cell Lung Cancer (NSCLC)

Surge 171

Cancer is an alarming global health concern. In 2016, it is estimated that approximately 27% of the cancer deaths will be due to lung and bronchus cancer. Drug resistance is a trending problem encountered by pharmaceutical and biotechnology companies developing anticancer drugs. It has been observed that chemotherapy might have reached a therapeutic glass ceiling in metastatic NSCLC. Cancer resistance can be acquired through dysfunctional DNA repair mechanism, epigenetics, cell-death inhibition, and drug efflux. Combination therapy brings the opportunity to re-establish current and obsolete FDA approved anti-cancer drugs by reducing the likelihood of cancer cells to develop resistance, and eliminating the dose-related off-target toxicities. This project aims to identify the novel drug combinations that would be capable of tackling the problems associated with acquired drug resistance. Here, we examined the response of NSCLC cell lines A549, H4006, H460, and H358 to independent treatment with FDA approved drugs: pemetrexed, quinacrine, cisplatin, paclitaxel, sorafenib, erlotinb, Px-866, oxaliplatin, and minocycline, in varying concentrations. The viabilities of the cell lines were assessed using cytotoxity assay and the IC50 values were obtained using the software Graphpad prism 4. Combination therapy was applied to the cell lines that expressed resistance to the drug, displayed an IC50 value above 10 µM, and the viability of the cell lines was assessed with the cytotoxicity assay. Results indicated that cell lines H460, H4006, H358 had an IC50 value of 4 µM when subjected to quinacrine. Though, H358 and H4006 cell lines yielded resistance to cisplatin. Quinacrine-cisplatin combination therapy was applied to the H358 cell line, but the viability was similar to that of independent treatment with quinacrine and cisplatin.